跳到主要內容

很遺憾,我們無法支援你的瀏覽器。如果可以,請升級到新版本,或使用 Mozilla Firefox、Microsoft Edge、Google Chrome 或 Safari 14 或更新版本。如果無法升級,而且需要支援,請將你的回饋寄給我們。

Elsevier
與我們共同出版

簡介

Jussi Hepojoki

Jussi Hepojoki

Session title: One Health Vaccines

University of Helsinki & University of Zürich, Finland/Switzerland

Dr. Jussi Hepojoki, based at the University of Helsinki (Docent/Associate professor in Virology) and University of Zürich (Privat Dozent in Viral discovery and molecular pathogenesis), is a virologist with a background in biochemistry and bioengineering. In Helsinki, Dr. Hepojoki holds Sigrid Jusélius senior researcher position, is a HiLIFE (Helsinki Institute of Life Sciences) research fellow and affiliates also to HOH (Helsinki One Health), whereas in Zürich Dr. Hepojoki is Titularprofessor and employed as a Wissenschaftlicher mitarbeiter (an Academic Associate). His research focuses on virus-host interactions, immune responses, virus discovery, molecular biology of viruses, and the development of molecular biology tools applicable e.g. to infectious disease diagnostics. Dr. Hepojoki did his PhD thesis on the structure and assembly of hantaviruses, and he has since contributed to structural and pathogenesis studies on hantaviruses, as well as to the development of Förster resonance energy transfer (TR-FRET)-based homogeneous (mix-and-read) diagnostic assays using e.g. hantaviruses as a model. Currently, Dr. Hepojoki’s group is, among other topics, studying mRNA delivery using inorganic nanoparticles utilizing Puumala orthohantavirus as one of the models. The details of Dr. Hepojoki’s past and recent publication activity can be accessed e.g. via Google Scholar (https://scholar.google.com/citations?user=-jpV0yYAAAAJ&hl=fiopens in new tab/window), ORCID (https://orcid.org/0000-0001-5699-214Xopens in new tab/window) or ResearcherID (https://www.webofscience.com/wos/author/record/W-4667-2017opens in new tab/window).